Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview.
Journal
American journal of clinical dermatology
ISSN: 1179-1888
Titre abrégé: Am J Clin Dermatol
Pays: New Zealand
ID NLM: 100895290
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
accepted:
20
03
2022
pubmed:
21
4
2022
medline:
2
8
2022
entrez:
20
4
2022
Statut:
ppublish
Résumé
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal (GI) tract that is subdivided into Crohn's disease (CD) and ulcerative colitis (UC). CD is characterized by involvement of the entire GI tract, while UC mainly affects the distal GI tract. Moreover, both CD and UC can present with extraintestinal manifestations (EIMs) of the disease affecting multiple organ systems including the hepatobiliary tract, kidney, bones, eyes, joints, and skin. These complications can cause significant morbidity and negatively impact the quality of life for IBD patients. Although the pathogenesis of EIMs is not clearly elucidated, it is postulated that the diseased GI mucosa similarly stimulates excess immune responses at the extraintestinal sites. Cutaneous EIMs occur in up to 15% of patients with IBD, often predating their IBD diagnosis. They are categorized into (1) specific, (2) reactive, (3) associated, and (4) treatment-induced. Here, we review the epidemiological, clinical, diagnostic, and histologic features of the most commonly described cutaneous EIMs of IBD along with their respective treatment options.
Identifiants
pubmed: 35441942
doi: 10.1007/s40257-022-00689-w
pii: 10.1007/s40257-022-00689-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
481-497Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
McDowell CFU, Haseeb M. Inflammatory Bowel Disease. [Updated 2021 Aug 31]. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing, https://www.ncbi.nlm.nih.gov/books/NBK470312/ .
Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205–17.
pubmed: 25732745
doi: 10.1038/nrgastro.2015.34
Windsor JW, Kaplan GG. Evolving epidemiology of IBD. Curr Gastroenterol Rep. 2019;21(8):40.
pubmed: 31338613
doi: 10.1007/s11894-019-0705-6
Aniwan S, Harmsen WS, Tremaine WJ, Loftus EV. Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010. Therap Adv Gastroenterol. 2019;12:1756284819827692.
pubmed: 30792818
pmcid: 6376543
doi: 10.1177/1756284819827692
Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology. 1991;100(1):143–9.
pubmed: 1983816
doi: 10.1016/0016-5085(91)90594-B
Calkins BM, Lilienfeld AM, Garland CF, Mendeloff AI. Trends in incidence rates of ulcerative colitis and Crohn’s disease. Dig Dis Sci. 1984;29(10):913–20.
pubmed: 6478982
doi: 10.1007/BF01312480
Roth MP, Petersen GM, McElree C, Feldman E, Rotter JI. Geographic origins of Jewish patients with inflammatory bowel disease. Gastroenterology. 1989;97(4):900–4.
pubmed: 2777043
doi: 10.1016/0016-5085(89)91495-9
StatPearls. 2021.
van Wijk F, Cheroutre H. Mucosal T cells in gut homeostasis and inflammation. Expert Rev Clin Immunol. 2010;6(4):559–66.
pubmed: 20594129
pmcid: 2976609
doi: 10.1586/eci.10.34
Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427–34.
pubmed: 17653185
doi: 10.1038/nature06005
Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology. 1990;98(2):464–9.
pubmed: 1688539
doi: 10.1016/0016-5085(90)90839-S
Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982–92.
pubmed: 26154136
doi: 10.1097/MIB.0000000000000392
Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (NY). 2011;7(4):235–41.
Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss inflammatory bowel disease cohort. Inflamm Bowel Dis. 2015;21(8):1794–800.
pubmed: 26020601
doi: 10.1097/MIB.0000000000000429
Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol. 2012;3:13.
pubmed: 22347192
pmcid: 3273725
Panackel C, John J, Krishnadas D, Vinayakumar KR. Metastatic Crohn’s disease of external genitalia. Indian J Dermatol. 2008;53(3):146–8.
pubmed: 19882017
pmcid: 2763745
doi: 10.4103/0019-5154.43207
Lauritano D, Boccalari E, Di Stasio D, Della Vella F, Carinci F, Lucchese A, et al. Prevalence of oral lesions and correlation with intestinal symptoms of inflammatory bowel disease: a systematic review. Diagnostics (Basel). 2019;9(3):77.
pmcid: 6787704
doi: 10.3390/diagnostics9030077
Laube R, Liu K, Schifter M, Yang JL, Suen MK, Leong RW. Oral and upper gastrointestinal Crohn’s disease. J Gastroenterol Hepatol. 2018;33(2):355–64.
pubmed: 28708248
doi: 10.1111/jgh.13866
Grave B, McCullough M, Wiesenfeld D. Orofacial granulomatosis—a 20-year review. Oral Dis. 2009;15(1):46–51.
pubmed: 19076470
doi: 10.1111/j.1601-0825.2008.01500.x
Lazzerini M, Bramuzzo M, Ventura A. Association between orofacial granulomatosis and Crohn’s disease in children: systematic review. World J Gastroenterol. 2014;20(23):7497–504.
pubmed: 24966621
pmcid: 4064096
doi: 10.3748/wjg.v20.i23.7497
Padmavathi B, Sharma S, Astekar M, Rajan Y, Sowmya G. Oral Crohn’s disease. J Oral Maxillofac Pathol. 2014;18(Suppl 1):S139–42.
pubmed: 25364165
pmcid: 4211224
Chi AC, Neville BW, Krayer JW, Gonsalves WC. Oral manifestations of systemic disease. Am Fam Physician. 2010;82(11):1381–8.
pubmed: 21121523
Lankarani KB, Sivandzadeh GR, Hassanpour S. Oral manifestation in inflammatory bowel disease: a review. World J Gastroenterol. 2013;19(46):8571–9.
pubmed: 24379574
pmcid: 3870502
doi: 10.3748/wjg.v19.i46.8571
Zbar AP, Ben-Horin S, Beer-Gabel M, Eliakim R. Oral Crohn’s disease: is it a separable disease from orofacial granulomatosis? A review. J Crohns Colitis. 2012;6(2):135–42.
pubmed: 22325167
doi: 10.1016/j.crohns.2011.07.001
Kim SK, Lee ES. Orofacial granulomatosis associated with Crohn’s disease. Ann Dermatol. 2010;22(2):203–5.
pubmed: 20548915
pmcid: 2883427
doi: 10.5021/ad.2010.22.2.203
Rice SA, Woo PN, El-Omar E, Keenan RA, Ormerod AD. Topical tacrolimus 0.1% ointment for treatment of cutaneous Crohn’s disease. BMC Res Notes. 2013;6:19.
pubmed: 23331739
pmcid: 3607997
doi: 10.1186/1756-0500-6-19
Dupuy A, Cosnes J, Revuz J, Delchier JC, Gendre JP, Cosnes A. Oral Crohn disease: clinical characteristics and long-term follow-up of 9 cases. Arch Dermatol. 1999;135(4):439–42.
pubmed: 10206051
doi: 10.1001/archderm.135.4.439
Sakuntabhai A, MacLeod RI, Lawrence CM. Intralesional steroid injection after nerve block anesthesia in the treatment of orofacial granulomatosis. Arch Dermatol. 1993;129(4):477–80.
pubmed: 8466220
doi: 10.1001/archderm.1993.01680250089013
Fedele S, Fung PP, Bamashmous N, Petrie A, Porter S. Long-term effectiveness of intralesional triamcinolone acetonide therapy in orofacial granulomatosis: an observational cohort study. Br J Dermatol. 2014;170(4):794–801.
pubmed: 24088036
pmcid: 4232906
doi: 10.1111/bjd.12655
Campbell HE, Escudier MP, Patel P, Challacombe SJ, Sanderson JD, Lomer MC. Review article: cinnamon- and benzoate-free diet as a primary treatment for orofacial granulomatosis. Aliment Pharmacol Ther. 2011;34(7):687–701.
pubmed: 21815899
doi: 10.1111/j.1365-2036.2011.04792.x
Espinoza I, Navarrete J, Benedetto J, Borzutzky A, Roessler P, Ortega-Pinto A. Orofacial granulomatosis and diet therapy: a review of the literature and two clinical cases. An Bras Dermatol. 2018;93(1):80–5.
pubmed: 29641703
pmcid: 5871368
doi: 10.1590/abd1806-4841.20185828
Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis. 2014;20(1):213–27.
pubmed: 24105394
doi: 10.1097/01.MIB.0000436959.62286.f9
Quezada S, Turner PL, Alexiev B, Daly B, Cross R. Severe refractory orofacial Crohn’s disease: report of a case. Dig Dis Sci. 2009;54(10):2290–5.
pubmed: 19082722
doi: 10.1007/s10620-008-0588-0
Williams DR, Coller JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn’s disease. Dis Colon Rectum. 1981;24(1):22–4.
pubmed: 7472097
doi: 10.1007/BF02603444
Sangwan YP, Schoetz DJ, Murray JJ, Roberts PL, Coller JA. Perianal Crohn’s disease. Results of local surgical treatment. Dis Colon Rectum. 1996;39(5):529–35.
pubmed: 8620803
doi: 10.1007/BF02058706
Singh B, McC Mortensen NJ, Jewell DP, George B. Perianal Crohn’s disease. Br J Surg. 2004;91(7):801–14.
pubmed: 15227686
doi: 10.1002/bjs.4613
Safar B, Sands D. Perianal Crohn’s disease. Clin Colon Rectal Surg. 2007;20(4):282–93.
pubmed: 20011424
pmcid: 2780223
doi: 10.1055/s-2007-991027
Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11(46):7227–36.
pubmed: 16437620
pmcid: 4725142
doi: 10.3748/wjg.v11.i46.7227
Schwartz DA, Tagarro I, Carmen Díez M, Sandborn WJ. Prevalence of fistulizing Crohn’s disease in the United States: estimate from a systematic literature review attempt and population-based database analysis. Inflamm Bowel Dis. 2019;25(11):1773–9.
pubmed: 31216573
pmcid: 6799946
doi: 10.1093/ibd/izz056
Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, Committee AGACP. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125(5):1508–30.
pubmed: 14598268
doi: 10.1016/j.gastro.2003.08.025
Egal A, London J, Lidove O, Atienza P, Etienney I. Anorectal manifestations in systemic diseases. Rev Med Interne. 2019;40(11):729–32.
pubmed: 31400822
doi: 10.1016/j.revmed.2019.07.009
Panés J, Rimola J. Perianal fistulizing Crohn’s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14(11):652–64.
pubmed: 28790453
doi: 10.1038/nrgastro.2017.104
Bataille F, Klebl F, Rümmele P, Schroeder J, Farkas S, Wild PJ, et al. Morphological characterisation of Crohn’s disease fistulae. Gut. 2004;53(9):1314–21.
pubmed: 15306592
pmcid: 1774207
doi: 10.1136/gut.2003.038208
de Zoeten EF, Pasternak BA, Mattei P, Kramer RE, Kader HA. Diagnosis and treatment of perianal Crohn disease: NASPGHAN clinical report and consensus statement. J Pediatr Gastroenterol Nutr. 2013;57(3):401–12.
pubmed: 23974063
doi: 10.1097/MPG.0b013e3182a025ee
Ickrath F, Stoevesandt J, Schulmeyer L, Glatzel C, Goebeler M, Kerstan A. Metastatic Crohn’s disease: an underestimated entity. J Dtsch Dermatol Ges. 2021;19(7):973–82.
pubmed: 34288476
Shields BE, Richardson C, Arkin L, Kornik R. Vulvar Crohn disease: diagnostic challenges and approach to therapy. Int J Womens Dermatol. 2020;6(5):390–4.
pubmed: 33898705
pmcid: 8060678
doi: 10.1016/j.ijwd.2020.09.007
Abboud ME, Frasure SE. Vulvar inflammation as a manifestation of Crohn’s disease. World J Emerg Med. 2017;8(4):305–7.
pubmed: 29123611
pmcid: 5675974
doi: 10.5847/wjem.j.1920-8642.2017.04.011
Bhoyrul B, Lyon C. Crohn’s disease of the vulva: a prospective study. J Gastroenterol Hepatol. 2018;33(12):1969–74.
pubmed: 29845642
doi: 10.1111/jgh.14291
Barret M, de Parades V, Battistella M, Sokol H, Lemarchand N, Marteau P. Crohn’s disease of the vulva. J Crohns Colitis. 2014;8(7):563–70.
pubmed: 24252167
doi: 10.1016/j.crohns.2013.10.009
Batra J, Goraya SK, Grewal S, Singh A. Metastatic Crohn’s disease of the vulva: a rare presentation. Indian Dermatol Online J. 2020;11(3):416–8.
pubmed: 32695706
pmcid: 7367556
doi: 10.4103/idoj.IDOJ_352_19
Granese R, Calagna G, Morabito G, Carriero C, Perino A, Tonni G, et al. Vulvar involvement in pediatric Crohn’s disease: a systematic review. Arch Gynecol Obstet. 2018;297(1):3–11.
pubmed: 28948431
doi: 10.1007/s00404-017-4539-x
Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–17.
pubmed: 15168363
doi: 10.1053/j.gastro.2004.01.063
Siroy A, Wasman J. Metastatic Crohn disease: a rare cutaneous entity. Arch Pathol Lab Med. 2012;136(3):329–32.
pubmed: 22372910
doi: 10.5858/arpa.2010-0666-RS
Burgdorf W. Cutaneous manifestations of Crohn’s disease. J Am Acad Dermatol. 1981;5(6):689–95.
pubmed: 6459345
doi: 10.1016/S0190-9622(81)70130-0
Aberumand B, Howard J. Metastatic Crohn’s disease: an approach to an uncommon but important cutaneous disorder. Biomed Res Int. 2017;2017:8192150.
pubmed: 28127561
pmcid: 5239966
doi: 10.1155/2017/8192150
Laftah Z, Bailey C, Zaheri S, Setterfield J, Fuller LC, Lewis F. Vulval Crohn’s disease: a clinical study of 22 patients. J Crohns Colitis. 2015;9(4):318–25.
pubmed: 25687208
doi: 10.1093/ecco-jcc/jjv037
Chakiri R, Baybay H, Hatimi AE, Gallouj S, Harmouch T, Mernissi FZ. Clinical and histological patterns and treatment of pyoderma gangrenosum. Pan Afr Med J. 2020;36:59.
pubmed: 32733629
pmcid: 7371440
doi: 10.11604/pamj.2020.36.59.12329
Keyal U, Liu Y, Bhatta AK. Dermatologic manifestations of inflammatory bowel disease: a review. Discov Med. 2018;25(139):225–33.
pubmed: 29906405
States V, O’Brien S, Rai JP, Roberts HL, Paas M, Feagins K, et al. Pyoderma gangrenosum in inflammatory bowel disease: a systematic review and meta-analysis. Dig Dis Sci. 2020;65(9):2675–85.
pubmed: 31925675
doi: 10.1007/s10620-019-05999-4
Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12(30):4819–31.
pubmed: 16937463
pmcid: 4087615
doi: 10.3748/wjg.v12.i30.4819
Xia FD, Liu K, Lockwood S, Butler D, Tsiaras WG, Joyce C, et al. Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum—a retrospective analysis. J Am Acad Dermatol. 2018;78(2):310-4.e1.
pubmed: 28947285
doi: 10.1016/j.jaad.2017.09.040
Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34(3):395–409 (quiz 10–12).
pubmed: 8609250
doi: 10.1016/S0190-9622(96)90428-4
Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006;333(7560):181–4.
pubmed: 16858047
pmcid: 1513476
doi: 10.1136/bmj.333.7560.181
Jockenhöfer F, Wollina U, Salva KA, Benson S, Dissemond J. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol. 2019;180(3):615–20.
pubmed: 29388188
doi: 10.1111/bjd.16401
Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239–54.
pubmed: 26614685
doi: 10.1093/ecco-jcc/jjv213
Greuter T, Navarini A, Vavricka SR. Skin manifestations of inflammatory bowel disease. Clin Rev Allergy Immunol. 2017;53(3):413–27.
pubmed: 28643285
doi: 10.1007/s12016-017-8617-4
Maverakis E, Marzano AV, Le ST, Callen JP, Brüggen MC, Guenova E, et al. Pyoderma gangrenosum. Nat Rev Dis Primers. 2020;6(1):81.
pubmed: 33033263
doi: 10.1038/s41572-020-0213-x
Marzano AV, Fanoni D, Antiga E, Quaglino P, Caproni M, Crosti C, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol. 2014;178(1):48–56.
pubmed: 24903614
pmcid: 4360193
doi: 10.1111/cei.12394
Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015;73(4):691–8.
pubmed: 26253362
doi: 10.1016/j.jaad.2015.06.021
Prajapati V, Man J, Brassard A. Pyoderma gangrenosum: common pitfalls in management and a stepwise, evidence-based, therapeutic approach. J Cutan Med Surg. 2009;13(Suppl 1):S2-11.
pubmed: 19480746
doi: 10.2310/7750.2009.00002
Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA. 2000;284(12):1546–8.
pubmed: 11000649
doi: 10.1001/jama.284.12.1546
Jolles S, Niclasse S, Benson E. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol. 1999;140(3):564–5.
pubmed: 10233301
doi: 10.1046/j.1365-2133.1999.02746.x
Marzano AV, Trevisan V, Lazzari R, Crosti C. Pyoderma gangrenosum: study of 21 patients and proposal of a “clinicotherapeutic” classification. J Dermatol Treat. 2011;22(5):254–60.
doi: 10.3109/09546631003686069
Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–9.
pubmed: 16188920
pmcid: 1856164
doi: 10.1136/gut.2005.074815
Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005;152(5):1059–61.
pubmed: 15888172
doi: 10.1111/j.1365-2133.2005.06467.x
Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn’s disease. Inflamm Bowel Dis. 2009;15(6):803–6.
pubmed: 18942748
doi: 10.1002/ibd.20748
Vidal D, Puig L, Gilaberte M, Alomar A. Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features. J Dermatol Treat. 2004;15(3):146–52.
doi: 10.1080/09546630410031909
Nousari HC, Lynch W, Anhalt GJ, Petri M. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol. 1998;134(12):1509–11.
pubmed: 9875186
doi: 10.1001/archderm.134.12.1509
von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137(6):1000–5.
pubmed: 9470924
doi: 10.1111/j.1365-2133.1997.tb01568.x
Sardar P, Guha P, Das NK, Gharami RC, Majumdar S, Banerjee D, et al. Ulcerative pyoderma gangrenosum in mixed connective tissue disorder: a rare association and role of azathioprine in the management. Indian J Dermatol. 2011;56(5):600–2.
pubmed: 22121294
pmcid: 3221239
doi: 10.4103/0019-5154.87172
Din RS, Tsiaras WG, Li DG, Mostaghimi A. Efficacy of systemic dapsone treatment for pyoderma gangrenosum: a retrospective review. J Drugs Dermatol. 2018;17(10):1058–60.
pubmed: 30365585
Cohen PR. Sweet’s syndrome—a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34.
pubmed: 17655751
pmcid: 1963326
doi: 10.1186/1750-1172-2-34
Cohen PR, Kurzrock R. Sweet’s syndrome revisited: a review of disease concepts. Int J Dermatol. 2003;42(10):761–78.
pubmed: 14521689
doi: 10.1046/j.1365-4362.2003.01891.x
von den Driesch P. Sweet’s syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994;31(4):535–56 (quiz 57–60).
pubmed: 8089280
doi: 10.1016/S0190-9622(94)70215-2
Ali M, Duerksen DR. Ulcerative colitis and Sweet’s syndrome: a case report and review of the literature. Can J Gastroenterol. 2008;22(3):296–8.
pubmed: 18354759
pmcid: 2662205
doi: 10.1155/2008/960585
Cohen PR, Kurzrock R. Sweet’s syndrome: a review of current treatment options. Am J Clin Dermatol. 2002;3(2):117–31.
pubmed: 11893223
doi: 10.2165/00128071-200203020-00005
Suehisa S, Tagami H. Treatment of acute febrile neutrophilic dermatosis (Sweet’s syndrome) with colchicine. Br J Dermatol. 1981;105(4):483.
pubmed: 7295564
doi: 10.1111/j.1365-2133.1981.tb00785.x
Amouri M, Masmoudi A, Ammar M, Boudaya S, Khabir A, Boudawara T, et al. Sweet’s syndrome: a retrospective study of 90 cases from a tertiary care center. Int J Dermatol. 2016;55(9):1033–9.
pubmed: 26967709
doi: 10.1111/ijd.13232
el Sherif AI, Bharija SC, Belhaj MS, Singh G. Dapsone in Sweet syndrome. Int J Dermatol. 1990;29(10):737.
pubmed: 2269575
Bourke JF, Berth-Jones J, Graham-Brown RA. Sweet’s syndrome responding to cyclosporin. Br J Dermatol. 1992;127(1):36–8.
pubmed: 1637692
doi: 10.1111/j.1365-2133.1992.tb14823.x
Seminario-Vidal L, Guerrero C, Sami N. Refractory Sweet’s syndrome successfully treated with rituximab. JAAD Case Rep. 2015;1(3):123–5.
pubmed: 27051705
pmcid: 4808708
doi: 10.1016/j.jdcr.2015.03.002
Agarwal A, Barrow W, Selim MA, Nicholas MW. Refractory subcutaneous Sweet syndrome treated with adalimumab. JAMA Dermatol. 2016;152(7):842–4.
pubmed: 27028556
doi: 10.1001/jamadermatol.2016.0503
Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882–94.
pubmed: 31498102
doi: 10.1016/S0140-6736(19)31778-7
Svecova D. Pemphigus vulgaris: a clinical study of 44 cases over a 20-year period. Int J Dermatol. 2015;54(10):1138–44.
pubmed: 26394602
doi: 10.1111/ijd.12644
Chmurova N, Svecova D. Pemphigus vulgaris: a 11-year review. Bratisl Lek Listy. 2009;110(8):500–3.
pubmed: 19750990
Kridin K, Zelber-Sagi S, Comaneshter D, Batat E, Cohen AD. Pemphigus and hematologic malignancies: a population-based study of 11,859 patients. J Am Acad Dermatol. 2018;78(6):1084-9.e1.
pubmed: 29198780
doi: 10.1016/j.jaad.2017.11.039
Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66(2):255–70.
pubmed: 29479654
doi: 10.1007/s12026-018-8986-7
Heelan K, Mahar AL, Walsh S, Shear NH. Pemphigus and associated comorbidities: a cross-sectional study. Clin Exp Dermatol. 2015;40(6):593–9.
pubmed: 25786337
doi: 10.1111/ced.12634
Seo JW, Park J, Lee J, Kim MY, Choi HJ, Jeong HJ, et al. A case of pemphigus vulgaris associated with ulcerative colitis. Intest Res. 2018;16(1):147–50.
pubmed: 29422810
pmcid: 5797262
doi: 10.5217/ir.2018.16.1.147
Kacar S, Sezgin O, Sahin T. Pemphigus vulgaris and ulcerative colitis. Am J Gastroenterol. 2002;97(2):507–8.
pubmed: 11866312
doi: 10.1111/j.1572-0241.2002.05520.x
Prendiville JS, Israel DM, Wood WS, Dimmick JE. Oral pemphigus vulgaris associated with inflammatory bowel disease and herpetic gingivostomatitis in an 11-year-old girl. Pediatr Dermatol. 1994;11(2):145–50.
pubmed: 8041655
doi: 10.1111/j.1525-1470.1994.tb00569.x
Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Ulcerative colitis associated with pemphigus: a population-based large-scale study. Scand J Gastroenterol. 2017;52(12):1360–4.
pubmed: 28954561
doi: 10.1080/00365521.2017.1380839
Takizawa H, Watanabe S, Takahashi M, Asakura H. Pemphigus vulgaris with asymptomatic pseudomembranous colitis. Am J Gastroenterol. 1996;91(8):1654–5.
pubmed: 8759684
Leshem YA, Hodak E, David M, Anhalt GJ, Mimouni D. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol. 2013;68(3):404–11.
pubmed: 23044076
doi: 10.1016/j.jaad.2012.08.010
Anandan V, Jameela WA, Sowmiya R, Kumar MMS, Lavanya P. Rituximab: a magic bullet for pemphigus. J Clin Diagn Res. 2017;11(4):WC01–6.
pubmed: 28571245
pmcid: 5449891
Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148(9):1031–6.
pubmed: 22710375
pmcid: 3658473
doi: 10.1001/archdermatol.2012.1522
Kasperkiewicz M, Shimanovich I, Meier M, Schumacher N, Westermann L, Kramer J, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol. 2012;166(1):154–60.
pubmed: 21910700
doi: 10.1111/j.1365-2133.2011.10585.x
Antonelli E, Bassotti G, Tramontana M, Hansel K, Stingeni L, Ardizzone S, et al. Dermatological manifestations in inflammatory bowel diseases. J Clin Med. 2021;10(2):364.
pubmed: 33477990
pmcid: 7835974
doi: 10.3390/jcm10020364
Thrash B, Patel M, Shah KR, Boland CR, Menter A. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol. 2013;68(2):211.e1-233.e1 (quiz 44–6).
doi: 10.1016/j.jaad.2012.10.036
Hagen JW, Swoger JM, Grandinetti LM. Cutaneous manifestations of Crohn disease. Dermatol Clin. 2015;33(3):417–31.
pubmed: 26143422
doi: 10.1016/j.det.2015.03.007
Roth N, Biedermann L, Fournier N, Butter M, Vavricka SR, Navarini AA, et al. Occurrence of skin manifestations in patients of the Swiss inflammatory bowel disease cohort study. PLoS ONE. 2019;14(1):e0210436.
pubmed: 30682031
pmcid: 6347222
doi: 10.1371/journal.pone.0210436
Cui RZ, Bruce AJ, Rogers RS. Recurrent aphthous stomatitis. Clin Dermatol. 2016;34(4):475–81.
pubmed: 27343962
doi: 10.1016/j.clindermatol.2016.02.020
Scully C, Porter S. Oral mucosal disease: recurrent aphthous stomatitis. Br J Oral Maxillofac Surg. 2008;46(3):198–206.
pubmed: 17850936
doi: 10.1016/j.bjoms.2007.07.201
Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, et al. Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD cohort study. Inflamm Bowel Dis. 2017;23(7):1174–81.
pubmed: 28452862
doi: 10.1097/MIB.0000000000001109
Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976;55(5):401–12.
doi: 10.1097/00005792-197609000-00004
Greuter T, Vavricka SR. Extraintestinal manifestations in inflammatory bowel disease—epidemiology, genetics, and pathogenesis. Expert Rev Gastroenterol Hepatol. 2019;13(4):307–17.
pubmed: 30791773
doi: 10.1080/17474124.2019.1574569
Karmiris K, Avgerinos A, Tavernaraki A, Zeglinas C, Karatzas P, Koukouratos T, et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease. J Crohns Colitis. 2016;10(4):429–36.
pubmed: 26721936
doi: 10.1093/ecco-jcc/jjv232
Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005;81(959):580–5.
pubmed: 16143688
pmcid: 1743347
doi: 10.1136/pgmj.2004.031633
Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol. 2008;26(3):265–73.
pubmed: 18640523
doi: 10.1016/j.clindermatol.2007.10.018
Apgar JT. Newer aspects of inflammatory bowel disease and its cutaneous manifestations: a selective review. Semin Dermatol. 1991;10(3):138–47.
pubmed: 1931561
Requena L, Requena C. Erythema nodosum. Dermatol Online J. 2002;8(1):4.
pubmed: 12165214
Blake T, Manahan M, Rodins K. Erythema nodosum—a review of an uncommon panniculitis. Dermatol Online J. 2014;20(4):22376.
pubmed: 24746312
Ubogy Z, Persellin RH. Suppression of erythema nodosum by indomethacin. Acta Derm Venereol. 1982;62(3):265–6.
pubmed: 6179377
Lehman CW. Control of chronic erythema nodosum with naproxen. Cutis. 1980;26(1):66–7.
pubmed: 7389399
Horio T, Danno K, Okamoto H, Miyachi Y, Imamura S. Potassium iodide in erythema nodosum and other erythematous dermatoses. J Am Acad Dermatol. 1983;9(1):77–81.
pubmed: 6886108
doi: 10.1016/S0190-9622(83)70110-6
Elizaga FV. Erythema nodosum and indomethacin. Ann Intern Med. 1982;96(3):383.
pubmed: 7059113
doi: 10.7326/0003-4819-96-3-383_2
Alloway JA, Franks LK. Hydroxychloroquine in the treatment of chronic erythema nodosum. Br J Dermatol. 1995;132(4):661–2.
pubmed: 7748760
doi: 10.1111/j.1365-2133.1995.tb08725.x
Gilchrist H, Patterson JW. Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management. Dermatol Ther. 2010;23(4):320–7.
pubmed: 20666819
doi: 10.1111/j.1529-8019.2010.01332.x
Reddy H, Shipman AR, Wojnarowska F. Epidermolysis bullosa acquisita and inflammatory bowel disease: a review of the literature. Clin Exp Dermatol. 2013;38(3):225–9 (quiz 9–30).
pubmed: 23517353
doi: 10.1111/ced.12114
Koga H, Prost-Squarcioni C, Iwata H, Jonkman MF, Ludwig RJ, Bieber K. Epidermolysis bullosa acquisita: the 2019 update. Front Med (Lausanne). 2018;5:362.
pubmed: 30687710
doi: 10.3389/fmed.2018.00362
Chen M, Kim GH, Prakash L, Woodley DT. Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen. Autoimmunity. 2012;45(1):91–101.
pubmed: 21955050
doi: 10.3109/08916934.2011.606450
Gupta R, Woodley DT, Chen M. Epidermolysis bullosa acquisita. Clin Dermatol. 2012;30(1):60–9.
pubmed: 22137228
pmcid: 3234994
doi: 10.1016/j.clindermatol.2011.03.011
Chen M, O’Toole EA, Sanghavi J, Mahmud N, Kelleher D, Weir D, et al. The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with Crohn’s disease have autoantibodies to type VII collagen. J Invest Dermatol. 2002;118(6):1059–64.
pubmed: 12060403
doi: 10.1046/j.1523-1747.2002.01772.x
Ungureanu L, Cosgarea R, Alexandru Badea M, Florentina Vasilovici A, Cosgarea I, Corina ȘS. Cutaneous manifestations in inflammatory bowel disease (review). Exp Ther Med. 2020;20(1):31–7.
pubmed: 32508989
Vodegel RM, Jonkman MF, Pas HH, de Jong MC. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol. 2004;151(1):112–8.
pubmed: 15270879
doi: 10.1111/j.1365-2133.2004.06006.x
Kim JH, Kim YH, Kim SC. Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases. Acta Derm Venereol. 2011;91(3):307–12.
pubmed: 21394418
doi: 10.2340/00015555-1065
Iranzo P, Herrero-González JE, Mascaró-Galy JM, Suárez-Fernández R, España A. Epidermolysis bullosa acquisita: a retrospective analysis of 12 patients evaluated in four tertiary hospitals in Spain. Br J Dermatol. 2014;171(5):1022–30.
pubmed: 24890437
doi: 10.1111/bjd.13144
Gürcan HM, Ahmed AR. Current concepts in the treatment of epidermolysis bullosa acquisita. Expert Opin Pharmacother. 2011;12(8):1259–68.
pubmed: 21254861
doi: 10.1517/14656566.2011.549127
Iwata H, Vorobyev A, Koga H, Recke A, Zillikens D, Prost-Squarcioni C, et al. Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J Rare Dis. 2018;13(1):153.
pubmed: 30180870
pmcid: 6122731
doi: 10.1186/s13023-018-0896-1
Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;164(1):10–22.
pubmed: 26641955
doi: 10.7326/M15-0729
Fréling E, Baumann C, Cuny JF, Bigard MA, Schmutz JL, Barbaud A, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110(8):1186–96.
pubmed: 26195181
doi: 10.1038/ajg.2015.205
Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8(12):1048–55.
pubmed: 20728573
doi: 10.1016/j.cgh.2010.07.022
Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev. 2014;13(1):15–9.
pubmed: 23777821
doi: 10.1016/j.autrev.2013.06.005
Hu JZ, Billings SD, Yan D, Fernandez AP. Histologic comparison of tumor necrosis factor-α inhibitor-induced psoriasis and psoriasis vulgaris. J Am Acad Dermatol. 2020;83(1):71–7.
pubmed: 31931086
doi: 10.1016/j.jaad.2020.01.006
Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, et al. Tumor necrosis factor-α inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol. 2017;76(2):334–41.
pubmed: 27720274
doi: 10.1016/j.jaad.2016.08.012
Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59(7):996–1001.
pubmed: 18576309
doi: 10.1002/art.23835
Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233–40.
pubmed: 20580412
doi: 10.1016/j.semarthrit.2010.04.003
Li SJ, Perez-Chada LM, Merola JF. TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis. 2019;4(2):70–80.
pubmed: 31093599
doi: 10.1177/2475530318810851
Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11–12):1318–27.
pubmed: 21957906
doi: 10.1111/j.1365-2036.2011.04866.x
Andrisani G, Marzo M, Celleno L, Guidi L, Papa A, Gasbarrini A, et al. Development of psoriasis scalp with alopecia during treatment of Crohn’s disease with infliximab and rapid response to both diseases to ustekinumab. Eur Rev Med Pharmacol Sci. 2013;17(20):2831–6.
pubmed: 24174369
Ezzedine K, Visseaux L, Cadiot G, Brixi H, Bernard P, Reguiai Z. Ustekinumab for skin reactions associated with anti-tumor necrosis factor-α agents in patients with inflammatory bowel diseases: a single-center retrospective study. J Dermatol. 2019;46(4):322–7.
pubmed: 30816581
doi: 10.1111/1346-8138.14816
Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63(4):567–77.
pubmed: 23468464
doi: 10.1136/gutjnl-2012-302853
Gregoriou S, Kazakos C, Christofidou E, Kontochristopoulos G, Vakis G, Rigopoulos D. Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatol. 2011;21(1):104–5.
pubmed: 21233062
doi: 10.1684/ejd.2011.1164
Adegbola SO, Pisani A, Sahnan K, Tozer P, Ellul P, Warusavitarne J. Medical and surgical management of perianal Crohn’s disease. Ann Gastroenterol. 2018;31(2):129–39.
pubmed: 29507460
pmcid: 5825943
Stringer EE, Nicholson TJ, Armstrong D. Efficacy of topical metronidazole (10 percent) in the treatment of anorectal Crohn’s disease. Dis Colon Rectum. 2005;48(5):970–4.
pubmed: 15785894
doi: 10.1007/s10350-004-0873-8
Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn’s disease: exploratory randomized controlled trial. Inflamm Bowel Dis. 2007;13(3):245–53.
pubmed: 17206671
doi: 10.1002/ibd.20073
Hughes LE. Surgical pathology and management of anorectal Crohn’s disease. J R Soc Med. 1978;71(9):644–51.
pubmed: 712742
pmcid: 1436266
doi: 10.1177/014107687807100904
Bouguen G, Trouilloud I, Siproudhis L, Oussalah A, Bigard MA, Bretagne JF, et al. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn’s disease in patients treated with infliximab. Aliment Pharmacol Ther. 2009;30(7):749–56.
pubmed: 19583709
doi: 10.1111/j.1365-2036.2009.04089.x
Vogel JD, Johnson EK, Morris AM, Paquette IM, Saclarides TJ, Feingold DL, et al. Clinical practice guideline for the management of anorectal abscess, fistula-in-ano, and rectovaginal fistula. Dis Colon Rectum. 2016;59(12):1117–33.
pubmed: 27824697
doi: 10.1097/DCR.0000000000000733
Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009;15(1):17–24.
pubmed: 18668682
doi: 10.1002/ibd.20608